Pneumonia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented By Drug Type (Quinolone, Macrolide, Aminopenicillin, Cephalosporins, Glycopeptide Antibiotics, Others), By Distribution Channel and Geography.

Market Snapshot

Market Snapshot
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Pneumonia Treatment Market is expected to register a CAGR of 8.2% during the forecast period. The major contributing factors for market growth are increasing the prevalence of pneumonia and increasing product approvals related to the treatment of pneumonia. According to the World Health Organization, the most common cause of pneumonia in children is Streptococcus pneumoniae. In 2017, around 808,694 children under the age of 5 were died due to pneumonia and it accounts for approximately 15% of death cause in children. Furthermore, in 2018, Lupin launched the generic version of Atovaquone Oral Suspension USP which was indicated for the treatment of pneumocystis jirovecii pneumonia. Hence these factors are expected to propel the pneumonia treatment market growth.

Scope of the Report

As per the scope of the report, pneumonia is an acute respiratory disease in which pus and fluid are filled in the small sacs, alveoli of the lung which makes breathing difficult. It is generally caused by Streptococcus Pneumoniae, Haemophilus influenzae, Pneumocystis jiroveci, and HIV infections. Pneumonia Treatment Market is segmented By Drug Type, Distribution Channel, and Geography.

By Drug Type
Quinolone
Macrolide
Aminopenicilin
Cephalosporins
Glycopeptide Antibiotics
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Aminopenicillin Segment is Expected to Exibhit a Steady Growth in the Pneumonia Treatment Market

  • Aminopenicillin is a group of antibiotics that are usually used for the treatment of upper and lower respiratory tract infections. Amoxicillin, penicillin-like drug is the first-line treatment of community-acquired pneumonia infection according to the Infectious Disease Society of America. Amoxicillin binds to penicillin-binding proteins that activates an autolytic enzyme which destroys the bacterial cell wall and thereby kills the bacterial cell.
  • Furthermore, the number of hospital stays is higher in the case of adults which makes them at a greater risk of hospital-acquired pneumonia, according to the study published in 2017 in the Journal of Infection.
  • Also, according to the study published in Age and Ageing in 2017, approximately 1.5% of people are diagnosed with hospital-acquired pneumonia. Thereby, the growing burden of pneumonia in geriatric population and the development of products is expected to drive the market in this segment
Pneumonia Treatment Market Trend Image.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global pneumonia treatment market due to the growing burden of pneumonia infection and increasing product approvals. According to the Centre for Disease Control and Prevention, over 250,000 people are treated for pneumonia and 50,000 people die due to it every year in the United States. Moreover, in 2019, Nabriva Therapeutics plc received an US FDA approval for Xenleta for treatment of adults with community-acquired pneumonia infection. Thus, such factors are expected to influence positively on the pneumonia treatment market.

Pneumonia Treatment Market - Growth Rate by Region

Competitive Landscape

Companies are taking initiatives related to pneumonia treatment to grow their presence in the market. For instance, in 2019, Melinta Therapeutics Inc., registered for supplemental New Drug Application for Baxdela, for treatment in adult patients of community-acquired pneumonia in hospital. Some of the companies which are currently dominating the market are Pfizer Inc., Baxter International Inc., Abbott Laboratories, Novartis AG, Teva Pharmaceuticals Inc., Akorn Inc., Allergan, Neopharma, Lupin Pharmaceuticals Inc., and Mylan Inc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Pneumonia

      2. 4.2.2 Product Approvals for Pneumonia Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 Quinolone

      2. 5.1.2 Macrolide

      3. 5.1.3 Aminopenicilin

      4. 5.1.4 Cephalosporins

      5. 5.1.5 Glycopeptide Antibiotics

      6. 5.1.6 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott

      2. 6.1.2 Allergan

      3. 6.1.3 Akorn Inc.

      4. 6.1.4 Baxter International Inc.

      5. 6.1.5 Lupin Pharmaceuticals Inc.

      6. 6.1.6 Mylan Inc.

      7. 6.1.7 Neopharma

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Teva Pharmaceuticals Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 8.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Pfizer Inc., Teva Pharmaceuticals Inc., Mylan Inc., Abbott, Baxter International are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!